IP Library Granted Patent US 7,563,802
Granted Patent B2
US 7,563,802 · App. 11/960,845 · Granted Jul 21, 2009

Spirocyclic heterocyclic derivatives and methods of their use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,563,802
App. No.
11/960,845
Granted
Jul 21, 2009
Kind
B2
Abstract

Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.

Claims (26)

1. A method of inhibiting or treating pain comprising administering to a patient in need thereof an effective amount of a compound which is 4-[(4-N,N-diethylaminocarbonyl)-phenyl]-spiro[5-hydroxy-2H,1-benzopyran-2,4′-piperidine] or a pharmaceutically acceptable salt thereof.

2. A method according to claim 1 wherein the pain is selected from the group consisting of acute pain and chronic pain.

3. A method according to claim 2 wherein the pain is acute pain.

4. A method according to claim 2 wherein the pain is chronic pain.

5. A method according to claim 1 wherein the pain is selected from the group consisting of nociceptive pain, inflammatory pain, visceral pain, somatic pain, neuralgia, neuropathic pain, AIDS pain, cancer pain, phantom pain, psychogenic pain, pain resulting from hyperalgesia, pain caused by rheumatoid arthritis, migraine and allodynia.

6. A method according to claim 5 wherein the pain is neuropathic pain.

7. A method according to claim 1 wherein the compound is in the form of a hydrochloride salt.

8. A method of inhibiting or treating pain comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising, in combination with a pharmaceutically acceptable carrier, a compound which is 4-[(4-N,N-diethylaminocarbonyl)-phenyl]-spiro[5-hydroxy-2H,1-benzopyran-2,4′-piperidine] or a pharmaceutically acceptable salt thereof.

9. A method according to claim 8 wherein the pain is selected from the group consisting of acute pain and chronic pain.

10. A method according to claim 9 wherein the pain is acute pain.

11. A method according to claim 9 wherein the pain is chronic pain.

12. A method according to claim 8 wherein the pain is selected from the group consisting of nociceptive pain, inflammatory pain, visceral pain, somatic pain, neuralgia, neuropathic pain, AIDS pain, cancer pain, phantom pain, psychogenic pain, pain resulting from hyperalgesia, pain caused by rheumatoid arthritis, migraine and allodynia.

13. A method according to claim 12 wherein the pain is neuropathic pain.

14. A method according to claim 8 wherein the compound is in the form of a hydrochloride salt.

15. A method of inhibiting or treating pain comprising administering to a patient in need thereof an effective amount of a compound which is 4-[(4-N,N-diethylaminocarbonyl-2-hydroxy)phenyl]-spiro[2H,1-benzopyran-2,4′-piperidine] or a pharmaceutically acceptable salt thereof.

16. A method according to claim 15 wherein the pain is selected from the group consisting of acute pain and chronic pain.

17. A method according to claim 16 wherein the pain is acute pain.

18. A method according to claim 16 wherein the pain is chronic pain.

19. A method according to claim 15 , wherein the pain is selected from the group consisting of nociceptive pain, inflammatory pain, visceral pain, somatic pain, neuralgia, neuropathic pain, AIDS pain, cancer pain, phantom pain, psychogenic pain, pain resulting from hyperalgesia, pain caused by rheumatoid arthritis, migraine and allodynia.

20. A method according to claim 19 wherein the pain is neuropathic pain.

21. A method of inhibiting or treating pain comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising, in combination with a pharmaceutically acceptable carrier, a compound which is 4-[(4-N,N-diethylaminocarbonyl-2-hydroxy)phenyl]-spiro[2H,1-benzopyran-2,4′-piperidine] or a pharmaceutically acceptable salt thereof.

22. A method according to claim 21 wherein the pain is selected from the group consisting of acute pain and chronic pain.

23. A method according to claim 22 wherein the pain is acute pain.

24. A method according to claim 22 wherein the pain is chronic pain.

25. A method according to claim 21 , wherein the pain is selected from the group consisting of nociceptive pain, inflammatory pain, visceral pain, somatic pain, neuralgia, neuropathic pain, AIDS pain, cancer pain, phantom pain, psychogenic pain, pain resulting from hyperalgesia, pain caused by rheumatoid arthritis, migraine and allodynia.

26. A method according to claim 25 wherein the pain is neuropathic pain.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2015
From: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
To: CALIXA THERAPEUTICS, INC.; ADOLOR CORPORATION; CUBIST PHARMACEUTICALS, INC.
Reel/Frame 036180/0070 →
SECURITY AGREEMENT Recorded Nov 20, 2012
From: CUBIST PHARMACEUTICALS, INC.; ADOLOR CORPORATION; CALIXA THERAPEUTICS, INC.; CUBIST PHARMACEUTICALS HOLDINGS, INC.; CUBIST PHARMACEUTICALS U.S.
To: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
Reel/Frame 029339/0669 →